Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00084
|
|||||
| Drug Name |
Amphetamine
|
|||||
| Synonyms |
Amphetamine (tamper and abuse-resistant, Bio-MD/MPAR, ADHD); Amphetamine (tamper and abuse-resistant, Bio-MD/MPAR, ADHD), PharmacoFore; PF-08 (Bio-MD/MPAR/prodrug/oral, ADHD), PharmacoFore
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Attention deficit hyperactivity disorder [ICD11:6A05] | Approved | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C9H13N
|
|||||
| Canonical SMILES |
CC(CC1=CC=CC=C1)N
|
|||||
| InChI |
InChI=1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3
|
|||||
| InChIKey |
KWTSXDURSIMDCE-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 300-62-9
|
|||||
| Pharmaceutical Properties | Molecular Weight | 135.21 | Topological Polar Surface Area | 26 | ||
| Heavy Atom Count | 10 | Rotatable Bond Count | 2 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 1 | |||
| XLogP |
1.8
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103164180
,103810791
,103918755
,104302255
,10517686
,10524938
,10529136
,11336166
,11361405
,11462377
,11533323
,115861
,117525983
,125680154
,126677500
,127272449
,127272450
,127272451
,127272452
,127272453
,15297279
,24882028
,26746621
,31073245
,3249024
,35804947
,36519861
,36651428
,39909068
,46506414
,47216854
,48110531
,48415560
,49855301
,49855567
,51091776
,5340423
,53789505
,57321551
,57651795
,608004
,77830611
,7978700
,8150111
,8151914
,85209571
,85756449
,87765
,9717
,99302079
|
|||||
| ChEBI ID |
CHEBI:2679
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | 3-Oct | Transporter Info | Organic cation transporter 3 | Substrate | [2] | |
| DAT1 | Transporter Info | Sodium-dependent dopamine transporter | Substrate | [3] | ||
| NET | Transporter Info | Sodium-dependent noradrenaline transporter | Substrate | [3] | ||
| OCTN2 | Transporter Info | Organic cation/carnitine transporter 2 | Substrate | [4] | ||
| References | ||||||
| 1 | Amphetamine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Interaction of organic cation transporter 3 (SLC22A3) and amphetamine. J Neurochem. 2010 Jul;114(1):142-9. | |||||
| 3 | Amphetamines, new psychoactive drugs and the monoamine transporter cycle. Trends Pharmacol Sci. 2015 Jan;36(1):41-50. | |||||
| 4 | Novel organic cation transporter 2-mediated carnitine uptake in placental choriocarcinoma (BeWo) cells. J Pharmacol Exp Ther. 2005 Jan;312(1):192-8. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.